Alkermes, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$245.9M
Doctors Paid
54,197
Transactions
487,272
2024 Total
$16.6M
Payment Breakdown by Category
Research$163.0M (66.3%)
Consulting$17.7M (7.2%)
Food & Beverage$11.0M (4.5%)
Travel$6.2M (2.5%)
Royalty/License$549,782 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $163.0M | 52,429 | 66.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $46.6M | 18,247 | 18.9% |
| Consulting Fee | $17.7M | 3,214 | 7.2% |
| Food and Beverage | $11.0M | 384,789 | 4.5% |
| Travel and Lodging | $6.2M | 23,877 | 2.5% |
| Grant | $814,015 | 46 | 0.3% |
| Royalty or License | $549,782 | 14 | 0.2% |
| Education | $46,209 | 4,197 | 0.0% |
| Gift | $14,463 | 459 | 0.0% |
Payments by Type
Research
$163.0M
52,429 transactions
General
$83.0M
434,843 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | $13.8M | 0 | 1,233 |
| A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia | $12.2M | 0 | 1,351 |
| A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-1 | $11.3M | 0 | 859 |
| A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine (ALKS 4230) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) | $11.1M | 1 | 851 |
| A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder | $6.5M | 0 | 3,625 |
| A Two-Part, Phase 2/3, Randomized Study in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS) to Evaluate the Tolerability of ALKS 8700 Compared with DIMETHYL FUMARATE and the Long-Term Safety and Tolerability of ALKS 8700 | $5.8M | 0 | 3,049 |
| A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia | $5.5M | 0 | 6,710 |
| A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | $5.4M | 0 | 464 |
| A Phase 3 Study to Evaluate Weight Gain of ALKS 3831 Compared to Olanzapine in Adults with Schizophrenia | $5.2M | 0 | 9,502 |
| A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1 | $4.9M | 0 | 1,134 |
| A Phase 1, Single-Dose, Double-Blind, Placebo- and Active-Controlled, Randomized, 6-way Crossover Human Abuse Potential Study of Samidorphan | $4.4M | 0 | 67 |
| A Study to Evaluate the Effect of ALKS 3831 Compared to OLANZAPINE on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness | $4.3M | 0 | 2,149 |
| A Phase 1 Study to Evaluate the Effect of Multiple Doses of ALKS 3831 on QTc Interval in Subjects with Schizophrenia | $4.1M | 0 | 233 |
| A Phase 3 Study to Evaluate Weight Gain of ALKS 3831 Compared to OLANZAPINE in Adults with Schizophrenia | $3.9M | 0 | 1,416 |
| A Two-Part, Phase 2/3, Randomized Study in Subjects with Relapsing Remitting Multiple Sclerosis (RRMS) to Evaluate the Tolerability of ALKS 8700 Compared with Dimethyl Fumarate and the Long-Term Safety and Tolerability of ALKS 8700 | $3.6M | 0 | 1,915 |
| Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | $3.2M | 0 | 1,724 |
| A Phase 3 Study to Determine the Antipsychotic Efficacy and Safety of ALKS 3831 in Adult Subjects with Acute Exacerbation of Schizophrenia | $3.1M | 0 | 1,622 |
| A Phase II study of ALKS 4230 in combination with anti-pd-1 (Pembrolizumab) in patients with advanced or recurrent head and neck squamous cell cancer currently on treatment with anti-pd-(l)1 without having achieved a complete remission. | $2.7M | 0 | 123 |
| A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness | $2.7M | 0 | 483 |
| A Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of Naltrexone for use in Conjunction with Buprenorphine in Adults with Opioid Use Disorder Transitioning from Buprenorphine Maintenance Prior to First Dose of VIVITROL ( r) | $2.6M | 0 | 1,569 |
| A Phase 3 Multicenter Study of the Long-Term Safety and Tolerability of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults Who Have an Inadequate Response to Antidepressant Therapy (the FORWARD-2 Study) | $2.6M | 0 | 1,378 |
| A Randomized, Double-Blind, Parallel-Group Study in Healthy Subjects to Characterize Insulin Sensitivity and Lipid Metabolism in Response to Treatment with ALKS 3831 and Olanzapine | $2.4M | 0 | 43 |
| A Phase 2, Open-label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy Administered Subcutaneously in Patients With Advanced Cutaneous Melanoma or Intravenously in Patients With Advanced Mucosal Melanoma Who Have Previously Received Anti-PD-[L]-1 Therapy - ARTISTRY-6 | $2.1M | 0 | 358 |
| A Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of Low Dose Naltrexone for use in Conjunction with Buprenorphine in Adults with Opioid Use Disorder Prior to First Dose of VIVITROL | $2.0M | 0 | 5,269 |
| A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder | $1.8M | 0 | 785 |
| Pregnancy Registry Performance for Atypical Antipsychotics | $1.8M | 0 | 9 |
| A Phase II study of ALKS 4230 in combination with anti-pd-1 (Pembrolizumab) in patients with advanced or recurrent head and neck squamous cell cancer currently on treatment with anti-pd-(l)1 without having achieved a complete remission | $1.6M | 0 | 41 |
| A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth) | $1.6M | 0 | 802 |
| A Phase 1 Study to Evaluate the Effect of Multiple Doses of ALKS 8700 on the QTc Interval in Healthy Volunteers | $1.5M | 0 | 30 |
| Clinical and Immunologic Activity of ALKS 4230 on Tumor Microenvironment in Solid Tumor Patients - ARTISTRY-3 | $1.4M | 0 | 214 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Nancy Snyderman, Md, MD | Otolaryngology | Philadelphia, PA | $3.9M | $0 |
| Dr. Richard Gaynor, M.d, M.D | Hematology & Oncology | Indianapolis, IN | $3.2M | $0 |
| Cato Laurencin, M.d, M.D | Sports Medicine | Farmington, CT | $2.2M | $0 |
| Christopher Wright, Md, MD | Neurology | Boston, MA | $2.0M | $0 |
| Dr. Leslie Citrome, Md, Mph, MD, MPH | Psychiatry | Pomona, NY | $991,196 | $0 |
| Rakesh Jain, Md, MD | Psychiatry | Lake Jackson, TX | $817,998 | $0 |
| Rebecca Roma, Md, MD | Psychiatry | Pittsburgh, PA | $782,877 | $0 |
| Dr. Manoj Waikar, M.d, M.D | Psychiatry | Los Gatos, CA | $769,624 | $0 |
| Dr. Andreas Sidiropoulos, M.d., Ph.d, M.D., PH.D | Psychiatry | Detroit, MI | $759,673 | $0 |
| Dr. James Barker, M.d, M.D | Internal Medicine | Hickory, NC | $753,879 | $0 |
| Dr. Mark Reynolds, Md, MD | Psychiatry | Durham, NC | $750,277 | $0 |
| George Kruse, M.d, M.D | Psychiatry | Bronx, NY | $737,351 | $0 |
| Dr. Michael Measom, M.d, M.D | Psychiatry | Slc, UT | $734,078 | $0 |
| Vikram Mehra, M.d, M.D | Psychiatry | Katy, TX | $717,628 | $0 |
| Andrew Cutler, Md, MD | Psychiatry | Lakewood Ranch, FL | $705,627 | $0 |
| Dr. Heather Luing, Md, MD | Psychiatry | Saint Augustine, FL | $702,176 | $0 |
| Dr. Richard Jackson, M.d, M.D | Psychiatry | Bloomfield Hills, MI | $677,767 | $0 |
| Jasdeep Miglani, Md, MD | Psychiatry | Manassas, VA | $638,669 | $0 |
| Vithyalakshmi Selvaraj, M.b.b.s, M.B.B.S | Psychiatry | Omaha, NE | $632,798 | $0 |
| Suresh Sureddi, M.d, M.D | Psychiatry | Plano, TX | $610,431 | $0 |
| Patricio Escalona, M.d, M.D | Psychiatry | Albuquerque, NM | $608,327 | $0 |
| Carmen Pinto, M.d, M.D | Psychiatry | Elizabethtown, KY | $602,039 | $0 |
| Jon Jackson, Md, MD | Psychiatry | Jackson, MS | $588,878 | $0 |
| Josette Ragheb, Md, Phd, MD, PHD | Hematology | Apple Valley, CA | $570,079 | $0 |
| Kent Mcdaniel, M.d, M.D | Psychiatry | Glen Allen, VA | $544,679 | $0 |
Ad
Top Products
- ARISTADA $28.9M
- LYBALVI $23.4M
Associated Products (16)
- ARISTADA $28.9M
- LYBALVI $23.4M
- Aristada 441 mg $14.4M
- OLANZAPINE $9.5M
- ARISTADA 441MG $8.7M
- Vivitrol $8.3M
- Vivitrol 380mg $7.8M
- VIVITROL $3.8M
- DIMETHYL FUMARATE $3.6M
- Vivitrol 380 mg $2.4M
- Tecfidera $2.2M
- Aristada 441mg $1.3M
- Aristada, 1064mg Prefilled Syringe $1.2M
- VIVITROL 380MG $918,485
- Aristada 1064mg $482,790
- Aristada 662mg $91,248
Payment Categories
- Food & Beverage $11.0M
- Consulting $17.7M
- Travel & Lodging $6.2M
- Research $163.0M
- Royalties $549,782
About Alkermes, Inc.
Alkermes, Inc. has made $245.9M in payments to 54,197 healthcare providers, recorded across 487,272 transactions in the CMS Open Payments database. In 2024, the company paid $16.6M. The top product by payment volume is ARISTADA ($28.9M).
Payments were distributed across 289 medical specialties. The top specialty by payment amount is Psychiatry ($47.1M to 11,901 doctors).
Payment categories include: Food & Beverage ($11.0M), Consulting ($17.7M), Research ($163.0M), Travel & Lodging ($6.2M), Royalties ($549,782).
Alkermes, Inc. is associated with 16 products in the CMS Open Payments database, including ARISTADA, LYBALVI, and Aristada 441 mg.